Clinical trial · Interventional
Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
Phase II Trial of Motexafin Gadolinium for Treatment of Metastatic Renal Cell Carcinoma
NCT00134186CI-TRIAL-00000633completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to find out if renal cell (kidney) cancer that has spread to other parts of the body will respond to treatment with motexafin gadolinium (MGd).
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Renal Cell | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
| Kidney Neoplasms | Kidney Neoplasm | ONTOLOGY_EXACT | 0.90 |
| Urogenital Neoplasms | — | UNRESOLVED | — |
| Urologic Neoplasms | Urinary Tract Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| motexafin gadolinium | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Clinical response rate (CP, PR) to MGd in patients with confirmed progressive RCC (renal cell carcinoma)
Secondary outcomes (5)
- measure
- Clinical benefit rate (complete response [CR], partial response [PR], stable disease [SD])
- measure
- Time to progression
- measure
- Progression-free survival
- measure
- Overall survival and survival at 6 and 12 months
- measure
- Duration of clinical response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * ≥ 18 years old * Histologically confirmed renal cell carcinoma with clinically or pathologically confirmed progression * Ineligible for interleukin-2 (IL-2) treatment and/or have had 2 or fewer prior treatments * Measurable disease * Hemoglobin ≥ 9 mg/dL * ECOG performance status of 0, 1, or 2 * Willing and able to provide written informed consent Exclusion Criteria: * Inadequate bone marrow, renal and liver function by laboratory criteria * Absolute neutrophil count \< 1500/µL; * Platelet count \< 100,000/µL; * AST or ALT \> 2 x upper limit of normal (ULN); * Alkaline phosphatase \> 5 x ULN; * Total bilirubin \> 2 x ULN; * Creatinine \> 2.0 mg/dL. * Evidence of central nervous system metastases within past year * Uncontrolled hypertension * Known history of porphyria, G6PD deficiency or HIV
References
Publications (0)
Data not yet available
No reference posted for this study.